Search
Patexia Research
Case number 1:23-cv-00106

Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd. > Documents

Date Field Doc. No.Description (Pages)
Oct 31, 2024 268 ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 378 ). Ms. Anderson shall be TERMINATED as counsel of record in this matter. Signed by Chief District Judge Thomas S. Kleeh on 10/31/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 10/31/2024) (1)
Oct 30, 2024 267 MOTION to Withdraw as Attorney HAYLEE BERNAL ANDERSON'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 10/30/2024) (4)
Oct 21, 2024 266 STIPULATION AND ORDER REGARDING CASE MANAGEMENT. Signed by Chief District Judge Thomas S. Kleeh on 10/21/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 10/21/2024) (7)
Oct 15, 2024 265 STIPULATION and Proposed Order Regarding Case Management by Celltrion, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Gottlieb, Max) (Entered: 10/15/2024) (9)
Sep 30, 2024 264 ORDER DENYING DEFENDANT'S MOTIONS TO DISMISS. The Court DENIES WITHOUT PREJUDICE Defendant's motion (ECF No. 14 ). Defendant is granted LEAVE TO REFILE its motion challenging jurisdiction after the Federal Circuit addresses the appeal of ECF 225. Any such refiled motion shall be filed within fifteen (15) days after the Federal Circuit issues its decision. Signed by Chief District Judge Thomas S. Kleeh on 09/30/2024. (snc) (Entered: 09/30/2024) (2)
Sep 27, 2024 263 RESPONSE to Motion re (27 in 1:24-cv-00053-TSK, 334 in 1:24-md-03103-TSK-JPM, 261 in 1:23-cv-00106-TSK-JPM, 266 in 1:23-cv-00097-TSK-JPM, 254 in 1:24-cv-00039-TSK-JPM, 278 in 1:23-cv-00094-TSK-JPM, 215 in 1:23-cv-00089-TSK-JPM) MOTION for Status Conference filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 09/27/2024) (5)
Sep 16, 2024 262 ORDER of USCA for the Federal Circuit as to 259 Notice of Appeal filed by Samsung Bioepis Co., Ltd., 190 Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., 258 Notice of Appeal filed by Samsung Bioepis, CO., LTD., 175 Notice of Appeal, filed by Samsung Bioepis, CO., LTD., 203 Notice of Appeal, filed by Formycon AG, 261 Notice of Appeal filed by Formycon AG, 176 Notice of Appeal, filed by Samsung Bioepis Co., Ltd. (snc) Modified to adjust filing date on 9/16/2024 (snc). (Entered: 09/16/2024) (3)
Sep 13, 2024 261 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) () (8)
Sep 13, 2024 261 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. A) (6)
Sep 13, 2024 261 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. B) (18)
Sep 13, 2024 261 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. C) (30)
Sep 13, 2024 261 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. D) (12)
Sep 3, 2024 260 ORDER GRANTING MOTIONS TO WITHDRAW. For good cause, they are GRANTED (ECF Nos. 323 , 324 ). Renee M. Griffin and Yi Zhang shall be TERMINATED as counsel of record. Signed by Chief District Judge Thomas S. Kleeh on 09/03/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 09/03/2024) (1)
Aug 30, 2024 258 MOTION to Withdraw as Attorney RENEE M. GRIFFIN'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4)
Aug 30, 2024 259 MOTION to Withdraw as Attorney YI ZHANG'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4)
Aug 9, 2024 257 ORDER ON MOTION of USCA for the Federal Circuit as to 176 in 1:24-md-03103-TSK-JPM and 226 in 1:23-cv-00106-TSK-JPM Notice of Appeal filed by Samsung Bioepis Co., Ltd. (snc) (Entered: 08/09/2024) (2)
Aug 2, 2024 256 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) () (4)
Aug 2, 2024 256 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 23, 2024 Order ('572 patent)) (6)
Aug 2, 2024 256 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 30, 2024 Judgment ('601 patent)) (4)
Jul 16, 2024 255 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING: re 250 in 1:23-cv-00106-TSK-JPM and 259 in 1:24-md-03103-TSK-JPM. Notice of Appeal filed by Samsung Bioepis Co., Ltd. Federal Circuit USCA Case Number: 2024-2082. (snc) (Entered: 07/16/2024) (4)
Jul 15, 2024 254 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 262 , 264 . Signed by Chief District Judge Thomas S. Kleeh on 07/15/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/15/2024) (1)
Jul 12, 2024 251 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) () (4)
Jul 12, 2024 253 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 259 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/12/2024) () (1)
Jul 12, 2024 251 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) (Attachment Memorandum in Support) (6)
Jul 12, 2024 251 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) (Proposed Order) (1)
Jul 12, 2024 253 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 259 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/12/2024) (Attorney List) (23)
Jul 12, 2024 253 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 259 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/12/2024) (Docket Sheet) (30)
Jul 12, 2024 253 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 259 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/12/2024) (Notice of Appeal) (3)
Jul 12, 2024 253 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 259 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/12/2024) (Final Order) (3)
Jul 11, 2024 250 Notice of Appeal* (1)
Jul 10, 2024 249 ORDER FOR INJUNCTIVE RELIEF AGAINST SAMSUNG BIOEPIS. Signed by Chief District Judge Thomas S. Kleeh on 07/10/2024. (Copy to counsel for Regeneron and Samsung only) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) Modified to unseal per TSK Chambers (rr) on 7/11/2024 (snc). (Entered: 07/10/2024) (3)
Jul 9, 2024 248 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 243 ). Signed by Chief District Judge Thomas S. Kleeh on 07/09/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/09/2024) (1)
Jul 8, 2024 244 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 227 , 229 , 234 . Signed by Chief District Judge Thomas S. Kleeh on 07/08/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK-JPM (snc) (Entered: 07/08/2024) (1)
Jul 8, 2024 245 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 07/08/2024) () (3)
Jul 8, 2024 245 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 07/08/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) () (5)
Jul 3, 2024 242 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) () (4)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 1) (3)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 2) (2)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 3) (3)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 4) (2)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 5) (4)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 6) (2)
Jul 3, 2024 241 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 7) (2)
Jul 3, 2024 242 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) (Attachment Memorandum in Support) (6)
Jul 3, 2024 242 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) (Proposed Order) (1)
Jul 2, 2024 240 ***SEALED***ORDER ESTABLISHING SECURITY UNDER FEDERAL RULE OF CIVIL PROCEDURE 65(c). Signed by Chief District Judge Thomas S. Kleeh on 07/02/2024. (Copy to counsel for Regeneron and Samsung only) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/02/2024) (0)
Jun 28, 2024 239 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG. USCA for the Federal Circuit USCA Case Number: 2024-2019. Case Manager: M. Ames. (Clerk confirmed with Federal Circuit (J. Phillips) that this second appeal was opened in error and that a termination letter would be issued.) (dk) (Entered: 07/01/2024) (4)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) () (8)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 1) (5)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 2) (7)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 3) (6)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 4) (3)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 5) (4)
Jun 26, 2024 238 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Proposed Order) (4)
Jun 25, 2024 236 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 200 ). Signed by Chief District Judge Thomas S. Kleeh on 06/25/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/25/2024) (1)
Jun 25, 2024 237 STIPULATION AND ORDER EXTENDING THE DEADLINE FOR SUBMISSION OF A PROPOSED ORDER ESTABLISHING SECURITY UNDER FED.R. CIV.P. 65(c). IT IS THEREFORE STIPULATED AND AGREED, that the parties' deadline to submit a Proposed Rule 65(c) Security Order(s) is extended to July l, 2024. Signed by Chief District Judge Thomas S. Kleeh on 06/25/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/25/2024) (4)
Jun 24, 2024 232 Redacted Order Granting Motions for Preliminary Injunction. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. (Filed as public Order per Chambers (rr)) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/24/2024) (30)
Jun 24, 2024 233 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) () (4)
Jun 24, 2024 235 STIPULATION AND [PROPOSED] ORDER EXTENDING THE DEADLINE FOR SUBMISSION OF A PROPOSED ORDER ESTABLISHING SECURITY UNDER FED. R. CIV. P. 65(c) by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (5)
Jun 24, 2024 233 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (Memorandum of Law in Support) (6)
Jun 24, 2024 233 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (Proposed Order) (1)
Jun 20, 2024 230 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re 176 in 1:24-md-03103-TSK-JPM, 226 in 1:23-cv-00106-TSK-JPM. Notice of Appeal filed by Samsung Bioepis Co., Ltd. Federal Circuit USCA Case Number: 2024-1965. (snc) (Entered: 06/20/2024) (4)
Jun 20, 2024 231 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 180 ). Signed by Chief District Judge Thomas S. Kleeh on 06/20/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/20/2024) (1)
Jun 19, 2024 228 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 06/19/2024) () (3)
Jun 19, 2024 228 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 06/19/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
Jun 17, 2024 227 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 176 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/17/2024) () (1)
Jun 17, 2024 227 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 176 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/17/2024) (Attorney List) (23)
Jun 17, 2024 227 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 176 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/17/2024) (Docket Sheet) (30)
Jun 17, 2024 227 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 176 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/17/2024) (Notice of Appeal) (3)
Jun 14, 2024 222 ORDER DENYING MOTIONS TO STRIKE RELATING TO THE ATWAL DECLARATION (ECF NOS. 168 , 171 . Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/14/2024) (5)
Jun 14, 2024 223 ***SEALED*** ORDER GRANTING MOTION FOR CLARIFICATION (ECF NO. 135 ). Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (Copy to counsel for Regeneron, Formycon and Samsung) (snc) (Entered: 06/14/2024) (0)
Jun 14, 2024 224 ORDER DENYING EMERGENCY MOTION TO STRIKE RELATING TO GRAHAM DECLARATION (ECF NO. [195-2]. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/14/2024) (4)
Jun 14, 2024 225 ***SEALED*** ORDER GRANTING MOTIONS FOR PRELIMINARY INJUNCTION. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (Copy ONLY to counsel for Regeneron and Samsung) (snc) (Entered: 06/14/2024) (0)
Jun 14, 2024 226 NOTICE OF APPEAL as to 225 Order on Motion to Seal, Order on Motion for Leave to File (Sealed) by Samsung Bioepis, CO., LTD. Associated Cases: 1:24-md-03103-TSK-JPM (DN 176); 1:23-cv-00106 (DN 225). Filing fee $; 605, receipt number WVNDC-3961010. Appeal Record due by 7/15/2024. (Law, Sandra) Modified to add document linkage on 6/17/2024 (dk). (Entered: 06/14/2024) (3)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) () (4)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Supplement Memo ISO) (8)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Proposed Order) (3)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 1) (2)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 2) (5)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 3) (9)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 4) (13)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 5) (3)
Jun 12, 2024 221 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 6) (5)
May 31, 2024 220 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) () (14)
May 31, 2024 220 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix A - Regeneron's Filings) (30)
May 31, 2024 220 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix B - Amgen's Filings) (30)
May 31, 2024 220 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix C - Mylan/Biocon's Filings) (30)
May 31, 2024 220 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis) (30)
May 30, 2024 219 ORDER EXTENDING TEMPORARY RESTRAINING ORDER: granting 236 , 218 and 149 Motions. Signed by Chief District Judge Thomas S. Kleeh on 05/30/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/30/2024) (3)
May 29, 2024 218 MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) () (5)
May 29, 2024 218 MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) (Proposed Order) (3)
May 28, 2024 216 ORDER. Regeneron's Motion to Partially Withdraw Motions for Preliminary Injunction is GRANTED 119 . The portions of Regeneron's preliminary injunction motions that do not relate to the 865 patent are hereby WITHDRAWN. Amgen's motion for clarification on this issue is GRANTED 142 . The Court AMENDS the preliminary injunction briefing schedule with respect to Amgen. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) (Entered: 05/28/2024) (2)
May 28, 2024 217 STIPULATION AND ORDER TO SUPPLEMENT PRELIMINARY INJUNCTION RECORD. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/28/2024) (13)
May 24, 2024 214 STIPULATION and proposed Order to Supplement Preliminary Injunction Record by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) (5)
May 24, 2024 215 STIPULATION and proposed Order to Supplement Preliminary Injunction Record (corrected to include Exhibit A) by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) () (5)
May 24, 2024 215 STIPULATION and proposed Order to Supplement Preliminary Injunction Record (corrected to include Exhibit A) by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) (Exhibit A) (8)
May 21, 2024 210 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 22 , 100 , 101 . Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK (snc) (Entered: 05/21/2024) (1)
May 21, 2024 211 ORDER REGARDING LIAISON COUNSEL. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) (Entered: 05/21/2024) (2)
May 21, 2024 212 ORDER DENYING CERTAIN MOTIONS AS MOOT. Regeneron's motion for guidance 36 and Amgen's motion requesting an expedited status conference 20 are DENIED AS MOOT. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) Modified to unseal on 5/21/2024; Order was sealed in error. NEF regen. (dk). (Entered: 05/21/2024) (1)
May 21, 2024 213 MOTION to Withdraw Motion to Partially Withdraw Motions for Preliminary Injunction by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/21/2024) (4)
May 20, 2024 209 ORDER. The parties are DIRECTED to file, on or before May 31, 2024, written proposals indicating which matters are appropriate for collective pretrial consideration and disposition while the case is designated as an MDL. Signed by Chief District Judge Thomas S. Kleeh on 5/20/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 05/20/2024) (1)
May 17, 2024 206 ORDER GRANTING MOTION FOR TEMPORARY RESTRAINING ORDER (ECF NO. 72 ). Signed by Chief District Judge Thomas S. Kleeh on 05/17/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/17/2024) (4)
May 17, 2024 207 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh, Scheduling Conference held on 5/17/2024. (Court Reporter Cindy Knecht) Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 05/17/2024) (0)
May 17, 2024 208 TRANSCRIPT of status conference held on 5/17/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 6/7/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/15/2024. Associated Cases: 1:24-md-03103-TSK et al.(ck) (Entered: 05/17/2024) (22)
May 16, 2024 203 ORDER GRANTING MOTION TO WITHDRAW APPEARANCES (ECF 181 , 163 ). The Clerk is DIRECTED to terminate J. Brett Milbourn and Joe Kronawitter of the law firm Horn Aylward & Bandy, LLC as limited appearance counsel for Plaintiff. Signed by Chief District Judge Thomas S Kleeh on 5/16/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(dk) (Entered: 05/16/2024) (2)
May 16, 2024 204 MOTION for Leave to File Under Seal by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/16/2024) () (4)
May 16, 2024 204 MOTION for Leave to File Under Seal by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/16/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
May 15, 2024 202 ORDER GRANTING 71 MOTION FOR LEAVE TO FILE UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 05/15/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/15/2024) (2)
May 14, 2024 198 ***SEALED*** ORDER GRANTING MOTION TO SEAL (ECF NO. 40 ). Signed by Chief District Judge Thomas S. Kleeh on 05/14/2024. (Copy to counsel) Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(snc) (Entered: 05/14/2024) (0)
May 14, 2024 199 ORDER GRANTING MOTION FOR LEAVE TO FILE INADVERTENTLY OMITTED EXHIBIT UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 05/14/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(snc) (Entered: 05/14/2024) (2)
May 14, 2024 200 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) () (5)
May 14, 2024 200 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Attachment Memorandum in Support) (6)
May 14, 2024 200 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Proposed Order) (2)
May 10, 2024 197 NOTICE by Regeneron Pharmaceuticals, Inc. Joint Notice of Pending Motions Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/10/2024) (14)
May 7, 2024 194 REPLY to Response to Motion re (207 in 1:23-cv-00094-TSK-JPM, 217 in 1:23-cv-00097-TSK-JPM, 168 in 1:23-cv-00089-TSK-JPM, 131 in 1:24-cv-00039-TSK, 754 in 1:22-cv-00061-TSK-JPM, 36 in 1:24-md-03103-TSK, 189 in 1:23-cv-00106-TSK-JPM) MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/07/2024) (4)
May 7, 2024 195 MOTION for Leave to File Inadvertently Omitted Exhibit UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Pogue, David) (Entered: 05/07/2024) () (5)
May 7, 2024 195 MOTION for Leave to File Inadvertently Omitted Exhibit UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Pogue, David) (Entered: 05/07/2024) (Proposed Order) (2)
May 6, 2024 192 Joint MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/06/2024) () (4)
May 6, 2024 192 Joint MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/06/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
May 5, 2024 190 RESPONSE to Motion re 189 MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Samsung Bioepis Co., Ltd.. (Law, Sandra) (Entered: 05/05/2024) (7)
May 5, 2024 191 RESPONSE to Motion re (36 in 1:24-md-03103-TSK, 189 in 1:23-cv-00106-TSK-JPM) MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Samsung Bioepis Co., Ltd.. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/05/2024) (7)
May 3, 2024 189 MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/03/2024) (6)
Apr 30, 2024 188 ORDER 29 GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 04/30/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 04/30/2024) (2)
Apr 29, 2024 185 ***SEALED***ORDER ADDRESSING PENDING MOTION TO SEAL (ECF NO. 182). Signed by Chief District Judge Thomas S. Kleeh on 04/29/2024. (Copy emailed to counsel) Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00106-TSK-JPM(snc) (Entered: 04/29/2024) (0)
Apr 29, 2024 186 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) () (5)
Apr 29, 2024 186 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) (Attachment Memorandum in Support) (7)
Apr 29, 2024 186 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) (Proposed Order) (2)
Apr 26, 2024 183 ORDER CANCELING STATUS CONFERENCES. On April 11, 2024, each of the cases became member cases of the MDL Case No. 1:24-md-3013. For that reason, the status conferences are CANCELED. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (1)
Apr 26, 2024 184 PRETRIAL ORDER #1: INITIAL SCHEDULING CONFERENCE. Scheduling Conference is set for 5/17/2024 11:00 AM by Zoom Videoconference before Chief District Judge Thomas S. Kleeh. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (10)
Apr 24, 2024 179 ORDER CONTINUING MAY 2, 2024 PERMANENT AND PRELIMINARY INJUNCTION HEARINGS. The Court will reschedule the preliminary and permanent injunction hearings, if necessary, by separate order. For reasons stated herein, the parties' Joint Motion for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings is also DENIED (ECF No. 9 ). Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 04/24/2024) (2)
Apr 24, 2024 180 ***SEALED*** ORDER ADDRESSING PENDING MOTIONS TO SEAL (ECF NOS. 176 , 177 ). Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. (Emailed to Counsel) Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00106-TSK-JPM (dk) (Entered: 04/24/2024) (0)
Apr 24, 2024 181 ORDER GRANTING DEFENDANT'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NOS. 153 , 172 ). The Clerk is DIRECTED to convert each motion to seal into the pleading that is attached. Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (dk) (Entered: 04/24/2024) (1)
Apr 23, 2024 178 Joint MOTION for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 04/23/2024) (9)
Apr 12, 2024 174 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 4/12/2024. (Emailed to Counsel) (dk) (Entered: 04/12/2024) (0)
Apr 11, 2024 172 NOTICE by Regeneron Pharmaceuticals, Inc. of Deposition of Peter Tessier (Ruby, Steven) (Entered: 04/11/2024) (4)
Apr 9, 2024 171 ORDER granting 169 Motion for Leave to Appear Pro Hac Vice for Lauren Martin filed by Samsung Bioepis Co., Ltd. Signed by Chief District Judge Thomas S. Kleeh on 4/9/2024. (jb) (Entered: 04/09/2024) (1)
Apr 8, 2024 164 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Iain Cockburn. (Ruby, Steven) (Entered: 04/08/2024) (1)
Apr 8, 2024 165 NOTICE by Regeneron Pharmaceuticals, Inc. of Appearance of Jordan L. Damron (Franks, Raymond) (Entered: 04/08/2024) (2)
Apr 8, 2024 166 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 4/8/2024. Copy to counsel of record.(cmd) (Entered: 04/08/2024) (0)
Apr 8, 2024 167 ***SEALED***ORDER. Signed by Chief District Judge Thomas S. Kleeh on 4/8/2024. (jb) (Copy to counsel of record by email) (Entered: 04/08/2024) (0)
Apr 8, 2024 169 MOTION for Leave to Appear Pro Hac Vice of Lauren Martin by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin)(Law, Sandra) (Entered: 04/08/2024) () (2)
Apr 8, 2024 170 Pro Hac Vice filing fee in the amount of $200.00 paid for Lauren Martin. Receipt Number: 100003874. (jb) (Entered: 04/08/2024) (0)
Apr 8, 2024 169 MOTION for Leave to Appear Pro Hac Vice of Lauren Martin by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin)(Law, Sandra) (Entered: 04/08/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin) (1)
Apr 4, 2024 163 MOTION to Withdraw Appearances of J. Brett Milbourn and Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/04/2024) (4)
Apr 3, 2024 161 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Denis Boyle. (Ruby, Steven) (Entered: 04/03/2024) (1)
Apr 2, 2024 160 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Holly Prentice. (Ruby, Steven) (Entered: 04/02/2024) (1)
Apr 1, 2024 159 REPLY to Response to Motion re 152 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 04/01/2024) (6)
Mar 28, 2024 158 RESPONSE in Opposition re 152 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike filed by Samsung Bioepis Co., Ltd.. (Taylor, Chad) (Entered: 03/28/2024) (6)
Mar 27, 2024 157 ORDER granting 156 Motion of Mary Charlotte Y. Carroll for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 3/27/2024. (dk) (Entered: 03/27/2024) (1)
Mar 26, 2024 154 **DOCUMENT FILED WITH INCORRECT CASE NUMBER. REFILED AT 156 . MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) Modified on 3/26/2024 (dk). (Entered: 03/26/2024) () (2)
Mar 26, 2024 155 Pro Hac Vice filing fee in the amount of $200.00 paid for Mary Charlotte Y. Carroll. Receipt Number: 100003868. (jb) (Entered: 03/26/2024) (0)
Mar 26, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) () (2)
Mar 26, 2024 154 **DOCUMENT FILED WITH INCORRECT CASE NUMBER. REFILED AT 156 . MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) Modified on 3/26/2024 (dk). (Entered: 03/26/2024) (Exhibit A-WVSB Receipt) (2)
Mar 26, 2024 154 **DOCUMENT FILED WITH INCORRECT CASE NUMBER. REFILED AT 156 . MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) Modified on 3/26/2024 (dk). (Entered: 03/26/2024) (Attachment A) (1)
Mar 26, 2024 154 **DOCUMENT FILED WITH INCORRECT CASE NUMBER. REFILED AT 156 . MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) Modified on 3/26/2024 (dk). (Entered: 03/26/2024) (Attachment B) (1)
Mar 26, 2024 154 **DOCUMENT FILED WITH INCORRECT CASE NUMBER. REFILED AT 156 . MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) Modified on 3/26/2024 (dk). (Entered: 03/26/2024) (Proposed Order) (1)
Mar 26, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Exhibit A-WVSB Receipt) (2)
Mar 26, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Attachment A) (1)
Mar 26, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Attachment B) (1)
Mar 26, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Proposed Order) (1)
Mar 22, 2024 148 ***SEALED*** ORDER granting 144 Motion to Seal. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. (Emailed to Counsel) (dk) (Entered: 03/22/2024) (0)
Mar 22, 2024 150 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. Copy to counsel. (cmd) (Entered: 03/22/2024) (0)
Mar 22, 2024 151 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. Copy to counsel.(cmd) (Entered: 03/22/2024) (0)
Mar 22, 2024 152 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 03/22/2024) (7)
Mar 21, 2024 140 ORDER granting 136 Motion of Alyssa J. Picard for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (dk) (Main Document 140 replaced to correct case numberon 3/21/2024. NEF regen) (dk). (Entered: 03/21/2024) (1)
Mar 21, 2024 141 ORDER granting 137 Motion for Leave to Appear Pro Hac Vice of Sven E. Henningson III. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (dk) (Entered: 03/21/2024) (1)
Mar 21, 2024 142 ORDER granting 138 Motion for Leave to Appear Pro Hac Vice of Grace W. Knofczynski. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (dk) (Entered: 03/21/2024) (1)
Mar 21, 2024 143 ORDER granting 132 Motion for Leave to Appear Pro Hac Vice of Abigail Clark on behalf of Samsung Bioepis Co., Ltd. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (dk) (Entered: 03/21/2024) (1)
Mar 21, 2024 145 DEFENDANT SAMSUNG BIOEPIS CO., LTD.S OPPOSITION TO 99 REGENERON PHARMACEUTICALS, INC.S MOTION FOR A PRELIMINARY INJUNCTION by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Samsung Bioepis Opposition to Preliminary Injunction, # 3 Attachment Clark Declaration, # 4 Exhibit 1 to Clark Declaration, # 5 Exhibit 2 to Clark Declaration, # 6 Exhibit 3 to Clark Declaration, # 7 Exhibit 4 to Clark Declaration, # 8 Exhibit 5 to Clark Declaration, # 9 Exhibit 6 to Clark Declaration, # 10 Exhibit 7 to Clark Declaration, # 11 Attachment Boyle Declaration, # 12 Exhibit A to Boyle Declaration, # 13 Exhibit 1 to Boyle Declaration, # 14 Exhibit 2 to Boyle Declaration, # 15 Exhibit 3 to Boyle Declaration, # 16 Exhibit 4 to Boyle Declaration, # 17 Exhibit 5 to Boyle Declaration, # 18 Exhibit 6 to Boyle Declaration, # 19 Exhibit 7 to Boyle Declaration, # 20 Exhibit 8 to Boyle Declaration, # 21 Exhibit 9 to Boyle Declaration, # 22 Exhibit 10 to Boyle Declaration, # 23 Exhibit 11 to Boyle Declaration, # 24 Exhibit 12 to Boyle Declaration, # 25 Exhibit 13 to Boyle Declaration, # 26 Exhibit 14 to Boyle Declaration, # 27 Exhibit 15 to Boyle Declaration, # 28 Exhibit 16 to Boyle Declaration, # 29 Exhibit 17 to Boyle Declaration, # 30 Exhibit 18 to Boyle Declaration, # 31 Exhibit 19 to Boyle Declaration, # 32 Exhibit 20 to Boyle Declaration, # 33 Attachment Tessier Declaration, # 34 Exhibit A to Tessier Declaration, # 35 Exhibit 1 to Tessier Declaration, # 36 Exhibit 2 to Tessier Declaration, # 37 Exhibit 3 to Tessier Declaration, # 38 Exhibit 4 to Tessier Declaration, # 39 Exhibit 5 to Tessier Declaration, # 40 Exhibit 6 to Tessier Declaration, # 41 Exhibit 7 to Tessier Declaration, # 42 Exhibit 8 to Tessier Declaration, # 43 Exhibit 9 to Tessier Declaration, # 44 Exhibit 10 to Tessier Declaration, # 45 Exhibit 11 to Tessier Declaration, # 46 Exhibit 12 to Tessier Declaration, # 47 Exhibit 13 to Tessier Declaration, # 48 Exhibit 14 to Tessier Declaration, # 49 Exhibit 15 to Tessier Declaration, # 50 Exhibit 16 to Tessier Declaration, # 51 Exhibit 17 to Tessier Declaration, # 52 Exhibit 18 to Tessier Declaration, # 53 Exhibit 19 to Tessier Declaration, # 54 Exhibit 20 to Tessier Declaration, # 55 Exhibit 21 to Tessier Declaration, # 56 Exhibit 22 to Tessier Declaration, # 57 Exhibit 23 to Tessier Declaration, # 58 Exhibit 24 to Tessier Declaration, # 59 Exhibit 25 to Tessier Declaration, # 60 Exhibit 26 to Tessier Declaration, # 61 Exhibit 27 to Tessier Declaration, # 62 Exhibit 28 to Tessier Declaration, # 63 Exhibit 29 to Tessier Declaration, # 64 Exhibit 30 to Tessier Declaration, # 65 Exhibit 31 to Tessier Declaration, # 66 Exhibit 32 to Tessier Declaration, # 67 Exhibit 33 to Tessier Declaration, # 68 Exhibit 34 to Tessier Declaration, # 69 Exhibit 35 to Tessier Declaration, # 70 Exhibit 36 to Tessier Declaration, # 71 Exhibit 37 to Tessier Declaration, # 72 Exhibit 38 to Tessier Declaration, # 73 Exhibit 39 to Tessier Declaration, # 74 Exhibit 40 to Tessier Declaration, # 75 Exhibit 41 to Tessier Declaration, # 76 Exhibit 42 to Tessier Declaration, # 77 Exhibit 43 to Tessier Declaration, # 78 Exhibit 44 to Tessier Declaration, # 79 Exhibit 45 to Tessier Declaration, # 80 Exhibit 46 to Tessier Declaration, # 81 Exhibit 47 to Tessier Declaration, # 82 Exhibit 48 to Tessier Declaration, # 83 Exhibit 49 to Tessier Declaration, # 84 Exhibit 50 to Tessier Declaration, # 85 Exhibit 51 to Tessier Declaration, # 86 Exhibit 52 to Tessier Declaration, # 87 Exhibit 53 to Tessier Declaration, # 88 Exhibit 54 to Tessier Declaration, # 89 Exhibit 55 to Tessier Declaration, # 90 Exhibit 56 to Tessier Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0)
Mar 21, 2024 146 Responsive Declaration of Dr. Holly Prentice, Ph.D. by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Prentice Declaration in support of Samsung Bioepis Opposition to Regeneron's Motion for Preliminary Injunction, # 3 Exhibit 1 to Prentice Declaration, # 4 Exhibit 2 to Prentice Declaration, # 5 Exhibit 3 to Prentice Declaration, # 6 Exhibit 4 to Prentice Declaration, # 7 Exhibit 5 to Prentice Declaration, # 8 Exhibit 6 to Prentice Declaration, # 9 Exhibit 7 to Prentice Declaration, # 10 Exhibit 8 to Prentice Declaration, # 11 Exhibit 9 to Prentice Declaration, # 12 Exhibit 10 to Prentice Declaration, # 13 Exhibit 11 to Prentice Declaration, # 14 Exhibit 12 to Prentice Declaration, # 15 Exhibit 13 to Prentice Declaration, # 16 Exhibit 14 to Prentice Declaration, # 17 Exhibit 15 to Prentice Declaration, # 18 Exhibit 16 to Prentice Declaration, # 19 Exhibit 17 to Prentice Declaration, # 20 Exhibit 18 to Prentice Declaration, # 21 Exhibit 19 to Prentice Declaration, # 22 Exhibit 20 to Prentice Declaration, # 23 Exhibit 21 to Prentice Declaration, # 24 Exhibit 22 to Prentice Declaration, # 25 Exhibit 23 to Prentice Declaration, # 26 Exhibit 24 to Prentice Declaration, # 27 Exhibit 25 to Prentice Declaration, # 28 Exhibit 26 to Prentice Declaration, # 29 Exhibit 27 to Prentice Declaration, # 30 Exhibit 28 to Prentice Declaration, # 31 Exhibit 29 to Prentice Declaration, # 32 Exhibit 30 to Prentice Declaration, # 33 Exhibit 31 to Prentice Declaration, # 34 Exhibit 32 to Prentice Declaration, # 35 Exhibit 33 to Prentice Declaration, # 36 Exhibit 34 to Prentice Declaration, # 37 Exhibit 35 to Prentice Declaration, # 38 Index 36 to Prentice Declaration, # 39 Exhibit 37 to Prentice Declaration, # 40 Exhibit 38 to Prentice Declaration, # 41 Exhibit 39 to Prentice Declaration, # 42 Exhibit 40 to Prentice Declaration, # 43 Exhibit 41 to Prentice Declaration, # 44 Exhibit 42 to Prentice Declaration, # 45 Exhibit 43 to Prentice Declaration, # 46 Exhibit 44 to Prentice Declaration, # 47 Exhibit 45 to Prentice Declaration, # 48 Exhibit 46 to Prentice Declaration, # 49 Exhibit 47 to Prentice Declaration, # 50 Exhibit 48 to Prentice Declaration, # 51 Exhibit 49 to Prentice Declaration, # 52 Exhibit 50 to Prentice Declaration, # 53 Exhibit 51 to Prentice Declaration, # 54 Exhibit 52 to Prentice Declaration, # 55 Exhibit 53 to Prentice Declaration, # 56 Exhibit 54 to Prentice Declaration, # 57 Exhibit 55 to Prentice Declaration, # 58 Exhibit 56 to Prentice Declaration, # 59 Exhibit 57 to Prentice Declaration, # 60 Exhibit 58 to Prentice Declaration, # 61 Exhibit 59 to Prentice Declaration, # 62 Exhibit 60 to Prentice Declaration, # 63 Exhibit 61 to Prentice Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0)
Mar 21, 2024 147 Responsive Declaration of Iain Cockburn, Ph.D. by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Cockburn Declaration in Support of Samsung Bioepis Opposition to Regeneron's Motion for Preliminary Injunction, # 3 Exhibit 1-22 to Cockburn Declaration, # 4 Exhibit 23 to Cockburn Declaration, # 5 Exhibit 24-30 to Cockburn Declaration, # 6 Exhibit 31-35 to Cockburn Declaration, # 7 Exhibit 36-50 to Cockburn Declaration, # 8 Exhibit 51 (part 1) to Cockburn Declaration, # 9 Exhibit 51 (part 2) to Cockburn Declaration, # 10 Exhibit 51 (part 3) to Cockburn Declaration, # 11 Exhibit 51 (part 4) to Cockburn Declaration, # 12 Exhibit 51 (part 5) to Cockburn Declaration, # 13 Exhibit 51 (part 6) to Cockburn Declaration, # 14 Exhibit 51 (part 7) to Cockburn Declaration, # 15 Exhibit 51 (part 8) to Cockburn Declaration, # 16 Exhibit 51 (part 9) to Cockburn Declaration, # 17 Exhibit 51 (part 10) to Cockburn Declaration, # 18 Exhibit 51 (part 11) to Cockburn Declaration, # 19 Exhibit 51 (part 12) to Cockburn Declaration, # 20 Exhibit 51 (part 13) to Cockburn Declaration, # 21 Exhibit 51 (part 14) to Cockburn Declaration, # 22 Exhibit 51 (part 15) to Cockburn Declaration, # 23 Exhibit 51 (part 16) to Cockburn Declaration, # 24 Exhibit 51 (part 17) to Cockburn Declaration, # 25 Exhibit 51 (part 18) to Cockburn Declaration, # 26 Exhibit 51 (part 19) to Cockburn Declaration, # 27 Exhibit 51 (part 20) to Cockburn Declaration, # 28 Exhibit 51 (part 21) to Cockburn Declaration, # 29 Exhibit 51 (part 22) to Cockburn Declaration, # 30 Exhibit 52-62 to Cockburn Declaration, # 31 Exhibit 63-83 to Cockburn Declaration, # 32 Exhibit 84 (parts 1-4) to Cockburn Declaration, # 33 Exhibit 85-90 to Cockburn Declaration, # 34 Exhibit 91 (part 1) to Cockburn Declaration, # 35 Exhibit 91 (part 2) to Cockburn Declaration, # 36 Exhibit 91 (part 3) to Cockburn Declaration, # 37 Exhibit 92-100 to Cockburn Declaration, # 38 Exhibit 101 to Cockburn Declaration, # 39 Exhibit 102 to Cockburn Declaration, # 40 Exhibit 103 to Cockburn Declaration, # 41 Exhibit 104 to Cockburn Declaration, # 42 Exhibit 105 to Cockburn Declaration, # 43 Exhibit 106 to Cockburn Declaration, # 44 Exhibit 107 to Cockburn Declaration, # 45 Exhibit 108 to Cockburn Declaration, # 46 Exhibit 109 to Cockburn Declaration, # 47 Exhibit 110 to Cockburn Declaration, # 48 Exhibit 111 to Cockburn Declaration, # 49 Exhibit 112 (part 1) to Cockburn Declaration, # 50 Exhibit 112 (part 2) to Cockburn Declaration, # 51 Exhibit 112 (part 3) to Cockburn Declaration, # 52 Exhibit 112 (part 4) to Cockburn Declaration, # 53 Exhibit 113 to Cockburn Declaration, # 54 Exhibit 114 to Cockburn Declaration4, # 55 Exhibit 115 to Cockburn Declaration, # 56 Exhibit 116 to Cockburn Declaration, # 57 Exhibit 117 (part 1) to Cockburn Declaration, # 58 Exhibit 117 (Part 2) to Cockburn Declaration, # 59 Exhibit 118 to Cockburn Declaration, # 60 Exhibit 119 to Cockburn Declaration, # 61 Exhibit 120 to Cockburn Declaration, # 62 Exhibit 121 to Cockburn Declaration, # 63 Exhibit 122 to Cockburn Declaration, # 64 Exhibit 123 to Cockburn Declaration, # 65 Exhibit 124-130 to Cockburn Declaration, # 66 Exhibit 131 to Cockburn Declaration, # 67 Exhibit 132 (part 1) to Cockburn Declaration, # 68 Exhibit 132 (part 2) to Cockburn Declaration, # 69 Exhibit 132 (part 3) to Cockburn Declaration, # 70 Exhibit 133 (part 1) to Cockburn Declaration, # 71 Exhibit 133 (part 2) to Cockburn Declaration, # 72 Exhibit 133 (part 3) to Cockburn Declaration, # 73 Exhibit 134 (part 1) to Cockburn Declaration, # 74 Exhibit 134 (part 2) to Cockburn Declaration, # 75 Exhibit 135 (part 1) to Cockburn Declaration, # 76 Exhibit 135 (part 2) to Cockburn Declaration, # 77 Exhibit 135 (part 3) to Cockburn Declaration, # 78 Exhibit 136 to Cockburn Declaration, # 79 Exhibit 137 (part 1) to Cockburn Declaration, # 80 Exhibit 137 (part 2) to Cockburn Declaration, # 81 Exhibit 138 to Cockburn Declaration, # 82 Exhibit 139 to Cockburn Declaration, # 83 Exhibit 140 to Cockburn Declaration, # 84 Exhibit 141 to Cockburn Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). (Entered: 03/22/2024) (0)
Mar 18, 2024 139 Pro Hac Vice Filing Fee in the amount of $600.00 paid for Alyssa J. Picard, Sven E. Henningson, III & Grace W. Knofczynski. Receipt Number: 100003858. (jb) (Main Document 139 replaced on 3/18/2024 with corrected case number on receipt) (jb). (Entered: 03/18/2024) (0)
Mar 15, 2024 136 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (2)
Mar 15, 2024 137 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (2)
Mar 15, 2024 138 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (2)
Mar 15, 2024 137 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 137 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 137 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 137 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 15, 2024 136 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 136 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 136 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 136 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 15, 2024 138 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 138 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 138 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 138 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 14, 2024 134 ORDER GRANTING MOTION 133 TO WITHDRAW EMERGENCY MOTION TO COMPEL. Defendant's Motion 133 to Withdraw is GRANTED. Defendant's Emergency Motion 129 to Compel is TERMINATED AS MOOT. Signed by Magistrate Judge James P. Mazzone on 3/14/2024. (dk) Modified to correct signing judge on 3/14/2024. NEF regen (dk). (Entered: 03/14/2024) (1)
Mar 14, 2024 135 Pro Hac Vice Filing fee received for Abigail Clark: $ 200.00, receipt number 100003849. (dk) (Entered: 03/14/2024) (0)
Mar 13, 2024 132 MOTION for Leave to Appear Pro Hac Vice of Abigail Clark by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 03/13/2024) () (2)
Mar 13, 2024 133 MOTION to Withdraw 129 Emergency MOTION to Compel as Moot by Samsung Bioepis Co., Ltd.. (Taylor, Chad) (Entered: 03/13/2024) (3)
Mar 13, 2024 132 MOTION for Leave to Appear Pro Hac Vice of Abigail Clark by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 03/13/2024) (Proposed Order) (1)
Mar 12, 2024 130 ORDER OF REFERRAL. The 129 motion is REFERRED to Magistrate Judge James P. Mazzone for disposition. In ruling on the motion, the Magistrate Judge is authorized to consider the record, conduct a hearing if necessary, and do all things proper to render a decision. Signed by Chief District Judge Thomas S Kleeh on 03/12/2024. (Copy to Judge Mazzone) (snc) (Entered: 03/12/2024) (1)
Mar 12, 2024 131 ORDER DIRECTING RESPONSE re 129 Emergency MOTION to Compel. Responses due by 3/13/2024. Signed by Magistrate Judge James P. Mazzone on 3/12/2024. (dk) Modified to correct signing judge on 3/12/2024. NEF regen. (dk) (Entered: 03/12/2024) (1)
Mar 11, 2024 127 ORDER GRANTING DEFENDANT SAMSUNG BIOEPIS CO. LTD'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 125 ). Signed by Chief District Judge Thomas S Kleeh on 3/11/2024. (dk) (Entered: 03/11/2024) (1)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) () (2)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Attachment Memorandum in Support of Motion to Compel) (18)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 1 to Memorandum in Support of Motion to Compel) (7)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 2 to Memorandum in Support of Motion to Compel) (7)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 3 to Memorandum in Support of Motion to Compel) (30)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 4 to Memorandum in Support of Motion to Compel) (15)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 5 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 6 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 7 to Memorandum in Support of Motion to Compel) (3)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 8 to Memorandum in Support of Motion to Compel) (30)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 9 to Memorandum in Support of Motion to Compel) (4)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 10 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 11 to Memorandum in Support of Motion to Compel) (3)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 12 to Memorandum in Support of Motion to Compel) (16)
Mar 11, 2024 129 Emergency MOTION to Compel by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 13 to Memorandum in Support of Motion to Compel) (2)
Mar 8, 2024 126 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for the Notices of Deposition for Dr. Bernhardt Trout and Dr. Ranjit Singh Atwal. (Law, Sandra) (Entered: 03/08/2024) (3)
Mar 6, 2024 121 MOTION for Leave to Supplement Opposition to Defendants' Motion Regarding Non-Party Discovery by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery)(Pogue, David) (Entered: 03/06/2024) () (5)
Mar 6, 2024 122 ORDER GRANTING REGENERON'S MOTION FOR LEAVE TO SUPPLEMENT OPPOSITION (ECF NO. 121 ). Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery [ECF No. 121-1] shall be SEPARATELY FILED. Signed by Chief District Judge Thomas S Kleeh on 3/6/2024. (dk) (Entered: 03/06/2024) (1)
Mar 6, 2024 123 REGENERON'S SUPPLEMENTAL OPPOSITION TO DEFENDANTS' MOTION REGARDING NON-PARTY DISCOVERY filed by Regeneron Pharmaceuticals, Inc. (Filed per 122 Order) (dk) (Entered: 03/06/2024) (6)
Mar 6, 2024 124 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for the Notice of Deposition of Dr. Sean Sheridan. (Law, Sandra) (Entered: 03/06/2024) (3)
Mar 6, 2024 121 MOTION for Leave to Supplement Opposition to Defendants' Motion Regarding Non-Party Discovery by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery)(Pogue, David) (Entered: 03/06/2024) (Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion) (6)
Mar 5, 2024 119 ORDER GRANTING DEFENDANT SAMSUNG BIOEPSIS CO., LTD'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 104 ). Signed by Chief District Judge Thomas S Kleeh on 3/5/2024. (dk) (Entered: 03/05/2024) (1)
Mar 4, 2024 113 ***SEALED*** ORDER granting 110 Motion to Seal. Signed by Chief District Judge Thomas S Kleeh on 3/4/2024. (Emailed to Counsel of Record) (dk) (Entered: 03/04/2024) (0)
Mar 4, 2024 114 ***SEALED*** ORDER granting 111 Motion to Seal. Signed by Chief District Judge Thomas S Kleeh on 3/4/2024. (Emailed to Counsel) (dk) (Entered: 03/04/2024) (0)
Mar 4, 2024 116 ***SEALED*** ORDER granting 112 Motion to Seal. Signed by Chief District Judge Thomas S Kleeh on 3/4/2024. (Emailed to Counsel) (dk) (Entered: 03/04/2024) (0)
Feb 29, 2024 109 NOTICE of Appearance by Michael W. Carey on behalf of Regeneron Pharmaceuticals, Inc. (Carey, Michael) (Entered: 02/29/2024) (2)
Feb 27, 2024 105 ***SEALED*** ORDER GRANTING PLAINTIFF'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NOS. 122, 103 Signed by Chief District Judge Thomas S Kleeh on 2/27/2024. (Emailed to Counsel) (dk) (Entered: 02/27/2024) (0)
Feb 27, 2024 107 ***SEALED*** ORDER granting 102 . Signed by Chief District Judge Thomas S Kleeh on 2/27/2024. (Emailed to Counsel) (dk) (Entered: 02/27/2024) (0)
Feb 23, 2024 100 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/23/2024. Copy emailed to counsel. (cmd) (Entered: 02/23/2024) (0)
Feb 23, 2024 101 STIPULATED PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/23/2024. (dk) (Entered: 02/23/2024) (30)
Feb 22, 2024 95 STIPULATION and Joint Request for Entry of Agreed Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 02/22/2024) () (5)
Feb 22, 2024 96 TRANSCRIPT of status conference held on 2/15/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 3/14/2024. Redacted Transcript Deadline set for 3/25/2024. Release of Transcript Restriction set for 5/22/2024. (ck) (Entered: 02/22/2024) (11)
Feb 22, 2024 97 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150004915 to SB150005395. (Law, Sandra) (Entered: 02/22/2024) (4)
Feb 22, 2024 98 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150005396 to SB150005434. (Law, Sandra) (Entered: 02/22/2024) (4)
Feb 22, 2024 99 MOTION FOR PRELIMINARY INJUNCTION AND INCORPORATED MEMORANDUM OF LAW by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Motion for Preliminary Injunction, # 3 Attachment Opening Brief In Support of Motion for Preliminary Injunction, # 4 Exhibit Trout Declaration, part 1, # 5 Exhibit Trout Declaration, part 2, # 6 Exhibit Trout Declaration, part 3, # 7 Exhibit Trout Declaration, part 4, # 8 Exhibit Trout Declaration, part 5, # 9 Exhibit Trout Declaration, part 6, # 10 Exhibit Trout Declaration, part 7, # 11 Exhibit Trout Declaration, part 8, # 12 Exhibit Trout Declaration, part 9, # 13 Exhibit Trout Declaration, part 10, # 14 Exhibit Trout Declaration, part 11, # 15 Exhibit Atwal Declaration, part 1, # 16 Exhibit Atwal Declaration, part 2, # 17 Exhibit Atwal Declaration, part 3, # 18 Exhibit Atwal Declaration, part 4, # 19 Exhibit Atwal Declaration, part 5, # 20 Exhibit Atwal Declaration, part 6, # 21 Exhibit Atwal Declaration, part 7, # 22 Exhibit Atwal Declaration, part 8, # 23 Exhibit Atwal Declaration, part 9, # 24 Exhibit Atwal Declaration, part 10, # 25 Exhibit Atwal Declaration, part 11, # 26 Exhibit Sheridan Declaration, part 1, # 27 Exhibit Sheridan Declaration, part 2, # 28 Exhibit Sheridan Declaration, part 3, # 29 Exhibit Sheridan Declaration, part 4, # 30 Exhibit Sheridan Declaration, part 5, # 31 Exhibit Sheridan Declaration, part 6, # 32 Exhibit Sheridan Declaration, part 7, # 33 Exhibit Sheridan Declaration, part 8, # 34 Exhibit Sheridan Declaration, part 9, # 35 Exhibit Sheridan Declaration, part 10, # 36 Exhibit Sheridan Declaration, part 11, # 37 Exhibit Sheridan Declaration, part 12, # 38 Exhibit Sheridan Declaration, part 13, # 39 Exhibit Clark Declaration, # 40 Exhibit Patel Declaration, # 41 Proposed Order)(Pogue, David) Modified on 2/23/2024 (cmd). (Entered: 02/22/2024) (0)
Feb 22, 2024 95 STIPULATION and Joint Request for Entry of Agreed Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 02/22/2024) (Proposed Order) (30)
Feb 20, 2024 93 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/20/2024. Copy to counsel. (cmd) (Entered: 02/20/2024) (0)
Feb 20, 2024 94 PLAINTIFF REGENERON PHARMACEUTICALS, INC.S MEMORANDUM OF LAW IN OPPOSITION 14 MOTION to Dismiss for Lack of Jurisdiction Pursuant to Fed. R. Civ. P. 12(b)(2) filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3 part 1, # 4 Exhibit 3 part 2, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11)(cmd) (Entered: 02/20/2024) (0)
Feb 15, 2024 88 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 2/15/2024. (Court Reporter Cindy Knecht) (jb) (Entered: 02/15/2024) (0)
Feb 15, 2024 89 ORDER FOLLOWING STATUS CONFERENCE. For the reasons stated on the record, the Court made the following rulings. Plaintiff Regeneron Pharmaceuticals, Inc.s Emergency Motion for Clarification of the Court's January 9, 2024 Order [ECF No. 95, 23cv89; ECF No. 96, 23cv94; ECF No. 80, 23cv97; and ECF No. 77 , 23cv106] is DENIED. Signed by Chief District Judge Thomas S Kleeh on 2/15/2024. (dk) (Entered: 02/15/2024) (2)
Feb 15, 2024 90 AMENDED BRIEFING SCHEDULE ON MOTIONS TO DISMISS AND AMENDED SCHEDULE FOR PRELIMINARY INJUNCTION PROCEEDINGS. Regeneron shall file individual responses to the motions to dismiss on or before 2/19/2024. Replies due by 2/26/2024. Regeneron is to file individual motions for preliminary injunction by 2/22/2024. Hearing on Regeneron's motions for preliminary injunction is set for 5/2/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Status Conference set for 5/13/2024 12:00 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 2/15/2024. (dk) (Entered: 02/15/2024) (4)
Feb 15, 2024 91 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Service of Subpoena. (Pogue, David) (Entered: 02/15/2024) (2)
Feb 14, 2024 83 Pro Hac Vice Filing fee received on behalf of J. Brett Milbourn and J. Kronawitter: $ 400.00, receipt number 100003837. (dk) (Entered: 02/14/2024) (0)
Feb 14, 2024 84 ORDER granting 80 Motion of Joe Kronawitter for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 2/14/2024. (dk) (Entered: 02/14/2024) (1)
Feb 14, 2024 85 ORDER granting 79 Motion of J. Brett Milbourn for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 2/14/2024. (dk) (Entered: 02/14/2024) (1)
Feb 14, 2024 86 RESPONSE to Motion re 77 Emergency MOTION for Clarification of the Court's January 9, 2024 Order filed by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)(Law, Sandra) (Entered: 02/14/2024) () (9)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) () (10)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 1) (28)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 2) (30)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 3) (30)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 4) (3)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 5) (4)
Feb 14, 2024 87 RESPONSE in Opposition re 81 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 6) (4)
Feb 14, 2024 86 RESPONSE to Motion re 77 Emergency MOTION for Clarification of the Court's January 9, 2024 Order filed by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)(Law, Sandra) (Entered: 02/14/2024) (Exhibit A) (29)
Feb 13, 2024 77 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) () (9)
Feb 13, 2024 78 ORDER. Responses, if any, to Plaintiff Regeneron Pharmaceuticals, Inc.'s Emergency Motion for Clarification of the Court's January 9, 2024 Order (ECF No. 77 ) shall be filed on or before February 15, 2024. Signed by Chief District Judge Thomas S Kleeh on 2/13/2024. (dk) (Main Document 78 replaced with corrected order on 2/13/2024. NEF regen.) (dk) (Entered: 02/13/2024) (2)
Feb 13, 2024 79 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) () (2)
Feb 13, 2024 80 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) () (2)
Feb 13, 2024 81 MOTION to Expedite Status Conference by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) () (8)
Feb 13, 2024 82 ORDER ON DEFENDANTS' EXPEDITED MOTION FOR STATUS CONFERENCE. The motions 81 are GRANTED. Status Conference set, via ZOOM videoconferencing, for 2/15/2024 11:30 AM before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 2/13/2024. (dk) (Entered: 02/13/2024) (2)
Feb 13, 2024 80 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Attachment) (2)
Feb 13, 2024 80 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Proposed Order) (1)
Feb 13, 2024 79 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Attachment WVSB Receipt) (2)
Feb 13, 2024 79 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Proposed Order) (1)
Feb 13, 2024 81 MOTION to Expedite Status Conference by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit A) (2)
Feb 13, 2024 81 MOTION to Expedite Status Conference by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit B) (9)
Feb 13, 2024 81 MOTION to Expedite Status Conference by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit C) (3)
Feb 13, 2024 77 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) (Exhibit A) (17)
Feb 13, 2024 77 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) (Exhibit B) (9)
Feb 2, 2024 75 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Samsung Bioepis Co., Ltd.'s First Set of Requests for Production to Regeneron (Nos. 1-39). (Pogue, David) (Entered: 02/02/2024) (2)
Feb 2, 2024 76 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Identification of Patents. (Pogue, David) (Entered: 02/02/2024) (2)
Jan 31, 2024 74 ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE: 43 Motion of Rochelle Krawetz for Leave to Appear Pro Hac Vice; granting 44 Motion of Shaun Mahaffy for Leave to Appear Pro Hac Vice; granting 45 Motion of Andrew Trask for Leave to Appear Pro Hac Vice; granting 46 Motion of Rebecca Carter for Leave to Appear Pro Hac Vice; granting 47 Motion of Adam Pan for Leave to Appear Pro Hac Vice; granting 48 Motion of Thomas Fletcher for Leave to Appear Pro Hac Vice; granting 49 Motion of Jennalee Beazley for Leave to Appear Pro Hac Vice; granting 54 Motion of Andrew Goldsmith for Leave to Appear Pro Hac Vice; granting 55 Motion of Kathryn Kayali for Leave to Appear Pro Hac Vice; granting 56 Motion of Renee Griffin for Leave to Appear Pro Hac Vice; granting 57 Motion of Teagan Gregory for Leave to Appear Pro Hac Vice; granting 58 Motion of Arthur Argall for Leave to Appear Pro Hac Vice; granting 68 Motion of Haylee Bernal Anderson for Leave to Appear Pro Hac Vice; granting 69 Motion of Jacob Hartman for Leave to Appear Pro Hac Vice. Signed by Chief District Judge Thomas S Kleeh on 1/31/2024. (dk) (Entered: 01/31/2024) (2)
Jan 30, 2024 73 Pro Hac Vice Filing fees received for Rhochelle Krawetz, Shaun Mahaffy, Andrew Trask, Rebecca Carter, Adam Pan, Thomas Fletcher, Jeannalee Beazley, Andrew Goldsmith, Kathryn Kayali, Renee Griffin, Teagan Gregory, Arthur J. Argall, III, Haylee Bernal Anderson, Jacob Hartman: $ 2800.00, receipt number 100003825. (dk) (Entered: 01/30/2024) (0)
Jan 29, 2024 72 ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/29/2024. (dk) (Entered: 01/29/2024) (2)
Jan 28, 2024 70 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Samsung Bioepis Co., Ltd.'s Objections and Responses to Regeneron Pharmaceutical Inc.'s First Set of Requests for Production. (Law, Sandra) (Entered: 01/28/2024) (3)
Jan 28, 2024 71 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Samsung Bioepis Co., Ltd.'s Production of Documents Bates Numbered SB150001336 to SB150004914. (Law, Sandra) (Entered: 01/28/2024) (3)
Jan 26, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) () (2)
Jan 26, 2024 69 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) () (2)
Jan 26, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Exhibit A) (6)
Jan 26, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Exhibit B) (1)
Jan 26, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Attachment WVSB Receipt) (2)
Jan 26, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Proposed Order) (1)
Jan 26, 2024 69 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Exhibit A) (1)
Jan 26, 2024 69 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Attachment WVSB Receipt) (2)
Jan 26, 2024 69 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/26/2024) (Proposed Order) (1)
Jan 25, 2024 67 ORDER GRANTING 66 JOINT MOTION TO PERMIT PARTIES' LOCAL COUNSEL TO ATTEND DEPOSITIONS BY TELEPHONE OR OTHER ELECTRONIC MEANS. Signed by Chief District Judge Thomas S Kleeh on 1/25/2024. (dk) (Entered: 01/25/2024) (1)
Jan 24, 2024 66 Joint MOTION for leave for Local Counsel to attend depositions by phone by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order)(Taylor, Chad) (Entered: 01/24/2024) () (6)
Jan 24, 2024 66 Joint MOTION for leave for Local Counsel to attend depositions by phone by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order)(Taylor, Chad) (Entered: 01/24/2024) (Proposed Order) (1)
Jan 23, 2024 64 Pro Hac Vice Filing fee in the amount of $200.00 for Matthew D Robson is paid. Receipt Number 100003815. (jb) (Entered: 01/23/2024) (0)
Jan 23, 2024 65 ORDER granting 62 Motion for Leave to Appear Pro Hac Vice (of Matthew D. Robson). Signed by Chief District Judge Thomas S Kleeh on 01/23/2024. (snc) (Entered: 01/23/2024) (1)
Jan 22, 2024 62 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Robson by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson)(Law, Sandra) (Entered: 01/22/2024) () (2)
Jan 22, 2024 63 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Notice of Service of Subpoena. (Pogue, David) (Entered: 01/22/2024) (2)
Jan 22, 2024 62 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Robson by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson)(Law, Sandra) (Entered: 01/22/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson) (1)
Jan 19, 2024 54 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 58 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 59 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150000606 to SB150001335. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 60 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s Objections and Responses to Regeneron Pharmaceutical Inc.'s 2nd Set of Requests for Production. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 61 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s Objections and Responses to Regeneron's Amended Notice of 30(b)(6) Deposition of Defendant Samsung Bioepis Co. Ltd.. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 54 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (1)
Jan 19, 2024 54 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit WVSB Receipt) (2)
Jan 19, 2024 54 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 19, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 19, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 19, 2024 58 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 58 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 58 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 58 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 19, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 17, 2024 53 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Amended Notice of 30(b)(6) Deposition of Defendant Samsung Bioepis Co., Ltd. (Pogue, David) (Entered: 01/17/2024) (2)
Jan 12, 2024 52 CERTIFICATE OF SERVICE by Samsung Bioepis Co., Ltd. for Defendant Samsung Bioepis Co. Ltd.'s First Set of Requests for Production to Regeneron Pharmaceuticals, Inc.. (Law, Sandra) (Entered: 01/12/2024) (3)
Jan 11, 2024 42 ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE. It is hereby ORDERED that the following pro hac vice applications are APPROVED and that the applicants may appear pro hac vice in this matter: 17 Raymond Nimrod; 18 Matthew Traupman; 19 Laura Fairneny; 20 Zachariah Summers, 27 Jennifer Brooks Crozier, 28 Natalie Kennedy, 29 Anish Desai, 30 Tom Yu, 31 Elizabeth Weiswasser, 32 Matthew Sieger, 33 Rocco Recce, 34 Christopher Pepe, 35 Priyata Patel, 36 Zhen Lin, 37 Kathryn Leicht; 38 Yi Zhang, 39 Kellie Van Beck. Signed by Chief District Judge Thomas S Kleeh on 1/11/2024. (dk) (Entered: 01/11/2024) (2)
Jan 11, 2024 43 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 44 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 46 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 47 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 48 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 49 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 50 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Identification of Patents. (Pogue, David) (Entered: 01/11/2024) (3)
Jan 11, 2024 51 NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) () (5)
Jan 11, 2024 47 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 47 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 47 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 47 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 51 NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) (Exhibit A) (7)
Jan 11, 2024 49 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 49 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 49 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 49 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 46 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 46 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 46 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 46 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 44 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 44 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 44 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 44 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 43 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 43 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 43 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 43 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 48 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 48 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 48 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 48 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 9, 2024 36 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) () (3)
Jan 9, 2024 37 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) () (3)
Jan 9, 2024 38 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) () (3)
Jan 9, 2024 39 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) () (3)
Jan 9, 2024 40 ORDER SETTING BRIEFING SCHEDULE ON MOTIONS TO DISMISS AND SETTING SCHEDULE FOR PRELIMINARY INJUNCTION PROCEEDINGS. Signed by Chief District Judge Thomas S Kleeh on 1/9/2024. (cmd) (Entered: 01/09/2024) (4)
Jan 9, 2024 N/A Set/Reset Scheduling Order Deadlines: Motion Hearing set for 5/2/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. (cmd) (Entered: 01/09/2024) (0)
Jan 9, 2024 41 Pro Hac Vice Filing fee: $ 2600.00, receipt number 100003803. (PHV fee for K. Van Beck, Y. Zhang, K. Leicht, Z. Lin, P. Patel, C. Pepe, R. Recce, M. Sieger, E. Weiswasser, T. Yu, A. Desai, N. Kennedy, J. Crozier) (snc) (Entered: 01/09/2024) (0)
Jan 9, 2024 37 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Exhibit A) (1)
Jan 9, 2024 37 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Attachment WVSB Receipt) (2)
Jan 9, 2024 37 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Proposed Order) (1)
Jan 9, 2024 38 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Exhibit A) (1)
Jan 9, 2024 38 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Attachment WVSB Receipt) (2)
Jan 9, 2024 38 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Proposed Order) (1)
Jan 9, 2024 39 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Exhibit A) (1)
Jan 9, 2024 39 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Attachment WVSB Receipt) (2)
Jan 9, 2024 39 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Proposed Order) (1)
Jan 9, 2024 36 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Exhibit A) (1)
Jan 9, 2024 36 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Attachment WVSB Receipt) (2)
Jan 9, 2024 36 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Proposed Order) (1)
Jan 8, 2024 26 TRANSCRIPT of Proceedings held on 1/5/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 1/29/2024. Redacted Transcript Deadline set for 2/8/2024. Release of Transcript Restriction set for 4/8/2024. (ck) (Entered: 01/08/2024) (48)
Jan 8, 2024 27 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 28 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 29 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 30 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 31 MOTION for Leave to Appear Pro Hac Vice of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 32 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 33 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 34 MOTION for Leave to Appear Pro Hac Vice of Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 35 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) () (3)
Jan 8, 2024 34 MOTION for Leave to Appear Pro Hac Vice of Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 34 MOTION for Leave to Appear Pro Hac Vice of Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 34 MOTION for Leave to Appear Pro Hac Vice of Christopher M. Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 32 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 32 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 32 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 27 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 27 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 27 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 30 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 30 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 30 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 33 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 33 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 33 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 31 MOTION for Leave to Appear Pro Hac Vice of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 31 MOTION for Leave to Appear Pro Hac Vice of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 31 MOTION for Leave to Appear Pro Hac Vice of Elizabeth S. Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 35 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 35 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 35 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 29 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 29 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 29 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 8, 2024 28 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Exhibit A) (1)
Jan 8, 2024 28 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Attachment WVSB Receipt) (2)
Jan 8, 2024 28 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/08/2024) (Proposed Order) (1)
Jan 5, 2024 21 SEALED ORDER GRANTING DEFENDANT SAMSUNG BIOEPIS CO. LTD.'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 15 ). Signed by Chief District Judge Thomas S Kleeh on 1/5/2024. (Emailed to Counsel)(dk) (Entered: 01/05/2024) (0)
Jan 5, 2024 23 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 1/5/2024. (Court Reporter Cindy Knecht) (jb) (Entered: 01/05/2024) (0)
Jan 5, 2024 24 Pro Hac Vice Filing fee: $ 800.00, receipt number 100003796 (PHV fee for Nimrod, Fairneny, Traupman and Summers) (snc) (Entered: 01/05/2024) (0)
Jan 5, 2024 25 Pro Hac Vice Filing fee: $ 200.00, receipt number 100003798 (For David Berl) (snc) (Entered: 01/05/2024) (0)
Jan 4, 2024 11 NOTICE of Appearance by Sandra K. Law on behalf of Samsung Bioepis Co., Ltd. (Law, Sandra) (Entered: 01/04/2024) (2)
Jan 4, 2024 12 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Attachment 4 replaced with flattened document on 1/5/2024) (dk). (Entered: 01/04/2024) () (2)
Jan 4, 2024 13 ORDER granting 12 Motion of David I. Berl for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 1/4/2024. (dk) (Entered: 01/04/2024) (1)
Jan 4, 2024 14 MOTION to Dismiss for Lack of Jurisdiction Pursuant to Fed. R. Civ. P. 12(b)(2) by Samsung Bioepis Co., Ltd.. (Law, Sandra) (Entered: 01/04/2024) (5)
Jan 4, 2024 16 Corporate Disclosure Statement by Samsung Bioepis Co., Ltd.. (Law, Sandra) (Entered: 01/04/2024) (5)
Jan 4, 2024 17 MOTION for Leave to Appear Pro Hac Vice of Raymond N. Nimrod by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 18 MOTION for Leave to Appear Pro Hac Vice of Matthew A. Traupman by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 19 MOTION for Leave to Appear Pro Hac Vice of Laura L. Fairneny by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 20 MOTION for Leave to Appear Pro Hac Vice of Zachariah B. Summers by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summers)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 17 MOTION for Leave to Appear Pro Hac Vice of Raymond N. Nimrod by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod) (1)
Jan 4, 2024 19 MOTION for Leave to Appear Pro Hac Vice of Laura L. Fairneny by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny) (1)
Jan 4, 2024 20 MOTION for Leave to Appear Pro Hac Vice of Zachariah B. Summers by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summers)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summe) (1)
Jan 4, 2024 12 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Attachment 4 replaced with flattened document on 1/5/2024) (dk). (Entered: 01/04/2024) (Exhibit A) (6)
Jan 4, 2024 12 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Attachment 4 replaced with flattened document on 1/5/2024) (dk). (Entered: 01/04/2024) (Exhibit B) (1)
Jan 4, 2024 12 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Attachment 4 replaced with flattened document on 1/5/2024) (dk). (Entered: 01/04/2024) (Attachment WVSB Receipt) (2)
Jan 4, 2024 12 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Attachment 4 replaced with flattened document on 1/5/2024) (dk). (Entered: 01/04/2024) (Proposed Order) (1)
Jan 4, 2024 18 MOTION for Leave to Appear Pro Hac Vice of Matthew A. Traupman by Samsung Bioepis Co., Ltd.. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupma) (1)
Dec 29, 2023 10 ORDER SCHEDULING STATUS CONFERENCE for 1/5/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 12/29/2023. (dk) (Entered: 12/29/2023) (2)
Dec 28, 2023 2 REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (dk) (Entered: 12/28/2023) (3)
Dec 28, 2023 3 VERIFICATION OF ATTORNEY ADMISSION to Attorneys A. Pan, A. Goldsmith, A. Trask, A. Desai, A. Argall, C. Pepe, D. Berl, E. Weiswasser, E. Oberwetter, H. Bernal Anderson, J. Beazley, K. Kayali, K. Leicht, K. Van Beck, M. Sieger, N. Kennedy, P. Patel, R. Carter, R. Griffin, R. Recce, S. Mahaffy, T. Gregory, T. Fletcher, T. Yu, Y. Zhang, Z. Lin. (dk) (Entered: 12/28/2023) (1)
Dec 28, 2023 6 Corporate Disclosure Statement by Regeneron Pharmaceuticals, Inc. (Pogue, David) (Main Document 6 replaced with flattened document on 12/29/2023) (dk). (Entered: 12/28/2023) (2)
Dec 28, 2023 7 ***SEALED*** ORDER granting 5 Motion to Seal . Signed by Chief District Judge Thomas S Kleeh on 12/28/2023. (Emailed to counsel) (dk) (Entered: 12/28/2023) (0)
Dec 28, 2023 9 Emergency MOTION for Entry of a Schedule for Preliminary Injunction Proceedings or in the Alternative an Emergency Status Conference by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 12/28/2023) () (13)
Dec 28, 2023 9 Emergency MOTION for Entry of a Schedule for Preliminary Injunction Proceedings or in the Alternative an Emergency Status Conference by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 12/28/2023) (Proposed Order) (4)
Dec 27, 2023 1 Complaint* (1)
Menu